Health · 3 views
Once-daily oral icotrokinra outperforms placebo in ulcerative colitis
For patients with moderately to severely active ulcerative colitis, oral icotrokinra, a peptide that blocks the interleukin-23 receptor, yields a clinical response at week 12 significantly more often than placebo, according to a study…
AI Summary
Oral icotrokinra, a peptide that blocks the interleukin‑23 receptor, produced a clinical response at week 12 in patients with moderately to severely active ulcerative colitis significantly more often than placebo. The finding comes from a study published in the October 15 issue of the New England Journal of Medicine. The trial focused on once‑daily dosing of the oral formulation.
AI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedMore from Health
Continue reading recent Health coverage
- Reprogramming tumor microenvironment could improve prospects for treatment of pancreatic cancerContinue reading
- Tegoprubart preserves kidney function better than tacrolimus in first-time transplant patients, trial suggestsContinue reading
- Melanoma vaccine reduces death or cancer recurrence by 42%Continue reading
- Chinese Drug Shows Benefit in HER2-Low Breast CancerContinue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow